Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Comparison With Rituximab.

IF 3.9 2区医学 Q1 CLINICAL NEUROLOGY

Annals of Clinical and Translational Neurology Pub Date : 2026-04-26 DOI:10.1002/acn3.70392

Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan

{"title":"Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Comparison With Rituximab.","authors":"Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan","doi":"10.1002/acn3.70392","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and compare it with rituximab.Methods: We conducted a single-center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab. The primary outcome is relapse, while the secondary outcomes are disability status and adverse events.Results: Twenty-two patients received ofatumumab for a median duration of 19.5 months (range 6-41). Among them, 18 patients (81.82%) remained relapse-free during follow-up. Annualized relapse rate (ARR) significantly decreased from 1.30 (95% CI 0.74-2.29) pretreatment to 0.12 (95% CI 0.04-0.35) during ofatumumab therapy (IRR 10.86, 95% CI 3.22-36.70, p < 0.001). Through propensity score matching, 11 patients in the ofatumumab group and 11 patients in the rituximab group were compared. Ofatumumab was observed to be associated with a significantly lower risk of a second attack (HR 0.233, 95% CI 0.061 to 0.893, p = 0.018) compared to rituximab. Adverse events were reported in 54.55% patients (6/11) treated with ofatumumab, most of which were mild and occurred after the initial dose.Interpretation: Ofatumumab was associated with a lower relapse risk compared with rituximab in patients with MOGAD.","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2026-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Translational Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/acn3.70392","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and compare it with rituximab.

Methods: We conducted a single-center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab. The primary outcome is relapse, while the secondary outcomes are disability status and adverse events.

Results: Twenty-two patients received ofatumumab for a median duration of 19.5 months (range 6-41). Among them, 18 patients (81.82%) remained relapse-free during follow-up. Annualized relapse rate (ARR) significantly decreased from 1.30 (95% CI 0.74-2.29) pretreatment to 0.12 (95% CI 0.04-0.35) during ofatumumab therapy (IRR 10.86, 95% CI 3.22-36.70, p < 0.001). Through propensity score matching, 11 patients in the ofatumumab group and 11 patients in the rituximab group were compared. Ofatumumab was observed to be associated with a significantly lower risk of a second attack (HR 0.233, 95% CI 0.061 to 0.893, p = 0.018) compared to rituximab. Adverse events were reported in 54.55% patients (6/11) treated with ofatumumab, most of which were mild and occurred after the initial dose.

Interpretation: Ofatumumab was associated with a lower relapse risk compared with rituximab in patients with MOGAD.

查看原文本刊更多论文

Ofatumumab治疗髓鞘少突胶质细胞糖蛋白抗体相关疾病：与利妥昔单抗的比较

目的：评价ofatumumab治疗髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）的疗效和安全性，并与利妥昔单抗进行比较。方法：我们进行了一项单中心观察性研究，包括22例MOGAD患者接受ofatumumab治疗，21例接受利妥昔单抗治疗。主要结局是复发，次要结局是残疾状态和不良事件。结果：22例患者接受了ofatumumab治疗，中位持续时间为19.5个月（范围6-41个月）。其中18例（81.82%）患者随访期间无复发。ofatumumab治疗期间，MOGAD患者的年化复发率（ARR）从预处理前的1.30 （95% CI 0.74-2.29）显著降低至0.12 (95% CI 0.04-0.35) （IRR 10.86, 95% CI 3.22-36.70, p）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Clinical and Translational Neurology Medicine-Neurology (clinical)

CiteScore

9.10

自引率

1.90%

发文量

218

审稿时长

8 weeks

期刊介绍： Annals of Clinical and Translational Neurology is a peer-reviewed journal for rapid dissemination of high-quality research related to all areas of neurology. The journal publishes original research and scholarly reviews focused on the mechanisms and treatments of diseases of the nervous system; high-impact topics in neurologic education; and other topics of interest to the clinical neuroscience community.